Johnson & Johnson opened a window into its eye health portfolio this week with the debut of a new corporate site.

Social media can be scary. But Alimera Sciences is convinced that with fastidious prep—and plenty of it—pharma companies should have nothing to fear.

The list the FDA published last week is not likely to cause broader damage to the reputations of companies named, experts say.

Pfizer is counting on some later-stage shots to carry the torch after its blockbuster Prevnar slows down. But it's stocking its early pipeline, too.

With new nods for Pfizer’s Xeljanz and AbbVie’s upadacitinib coming, makers of anti-inflammatory drugs will be feeling the heat from JAK inhibitors.

After pharma suffered an unexpected loss in this year's budget deal, the industry sees an opportunity to get some relief.

Former Novartis CEO Joe Jimenez was set to join the board of a leading hedge fund, but the plans are now on hold, WSJ reports.

Dova and its brand-new Doptelet could soon face off against Shionogi’s lusutrombopag, set for an FDA decision in August

Optimistic that Amgen’s pipeline will deliver enough growth to support its $118B market cap? Think again, one Wall Street firm argues.